Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

DLBCL - Diffuse Large B Cell Lymphoma: early-phase trial registry

7 of 8 indexed DLBCL - Diffuse Large B Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 7 currently recruiting · #2,176 of 28,707 conditions by registered trial count

DLBCL - Diffuse Large B Cell Lymphoma: 8 US clinical trials tracked, 7 recruiting.

DLBCL - Diffuse Large B Cell Lymphoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition dlbcl-diffuse-large-b-cell-lymphoma

OPEN 7 | RECR 88% | LATE 0 | EARLY 7 | RANK #2176 | SPON 2

Nearest open-share peer: Aortic Diseases (88% recruiting · 8 trials)

DLBCL - Diffuse Large B (th…88%Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near DLBCL - Diffuse Large B Cell Lymphoma

DLBCL - Diffuse Large B Cell Lymphoma lists 7 open slots (88% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for DLBCL - Diffuse Large B Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. DLBCL - Diffuse Large B Cell Lymphoma is recruiting above its size-band peers.

    7 of 8 indexed trials (87.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates DLBCL - Diffuse Large B Cell Lymphoma research.

    Memorial Sloan Kettering Cancer Center accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most DLBCL - Diffuse Large B Cell Lymphoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 42 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.

  4. DLBCL - Diffuse Large B Cell Lymphoma research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 23

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 3

Named interventions

Most-linked intervention names on DLBCL - Diffuse Large B Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Post-infusion radiation Radiation
1 trials
Bridging radiation therapy Radiation
1 trials
LTZ-301 Biological
1 trials
Liso-cel Biological
1 trials
P-CD19CD20-ALLO1 Biological
1 trials
SynKIR-310 Biological
1 trials
obinutuzumab Drug
1 trials
glofitamab Drug
1 trials

US sites by state

Facility locations filed on DLBCL - Diffuse Large B Cell Lymphoma trials. A trial with sites in several states counts in each.

New York 4 trials
Pennsylvania 3 trials
Tennessee 2 trials
New Jersey 2 trials
Nebraska 2 trials
California 2 trials
Washington 1 trials
Virginia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this DLBCL - Diffuse Large B Cell Lymphoma page

8 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This DLBCL - Diffuse Large B Cell Lymphoma condition card totals 8 registered trials; most-linked intervention Post-infusion radiation; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.